Zoetis Inc. (NYSE:ZTS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 0.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,354,907 shares of the company's stock after purchasing an additional 6,300 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.74% of Zoetis worth $655,482,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Mizuho Securities USA LLC grew its stake in Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Sarasin & Partners LLP lifted its holdings in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company's stock valued at $390,682,000 after purchasing an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new stake in shares of Zoetis in the first quarter valued at approximately $210,815,000. International Assets Investment Management LLC increased its stake in shares of Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock worth $183,652,000 after purchasing an additional 937,700 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company's stock worth $144,874,000 after purchasing an additional 824,843 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Trading Up 0.2 %

Shares of NYSE ZTS traded up $0.42 on Friday, reaching $177.13. 892,377 shares of the company traded hands, compared to its average volume of 2,538,095. The company has a 50 day moving average of $185.90 and a 200 day moving average of $180.45. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The stock has a market capitalization of $79.92 billion, a PE ratio of 33.22, a P/E/G ratio of 2.69 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Zoetis's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.36 earnings per share. On average, equities research analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis's payout ratio is currently 32.52%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a "buy" rating in a research note on Monday, August 12th. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a "buy" rating in a research report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a "strong-buy" rating in a report on Friday, August 9th. Finally, Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.